• Vivesto posted Q2 operating loss of SEK 8.63 million, narrowing from SEK 9.74 million a year earlier.
• Net loss improved to SEK 8.38 million; loss per share narrowed to SEK 0.76.
• Cash and short-term investments climbed to SEK 23.51 million; equity ratio rose 2 percentage points to 94%.
• Paccal Vet dog pilot study enrollment completed; topline data expected in Q3 2026, with 19 evaluable dogs included.
• Cantrixil IV dog PK/tox study delivered positive data supporting a planned Phase I AML study; CFO Björn Svanström started July 1.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vivesto AB published the original content used to generate this news brief on August 13, 2026, and is solely responsible for the information contained therein.